TY - JOUR AU - Molina, J. R. AU - Yang, P. AU - Cassivi, S. D. AU - Schild, S. E. AU - Adjei, A. A. PY - 2008 DA - 2008// TI - Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship JO - Mayo Clin Proc VL - 83 UR - https://doi.org/10.1016/S0025-6196(11)60735-0 DO - 10.1016/S0025-6196(11)60735-0 ID - Molina2008 ER - TY - JOUR AU - Folkman, J. PY - 1971 DA - 1971// TI - Tumor angiogenesis: therapeutic implications JO - N Engl J Med VL - 285 UR - https://doi.org/10.1056/NEJM197111182852108 DO - 10.1056/NEJM197111182852108 ID - Folkman1971 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Viallard, C. AU - Larrivée, B. PY - 2017 DA - 2017// TI - Tumor angiogenesis and vascular normalization: alternative therapeutic targets JO - Angiogenesis VL - 20 UR - https://doi.org/10.1007/s10456-017-9562-9 DO - 10.1007/s10456-017-9562-9 ID - Viallard2017 ER - TY - JOUR AU - Carmeliet, P. AU - Jain, R. K. PY - 2011 DA - 2011// TI - Molecular mechanisms and clinical applications of angiogenesis JO - Nature VL - 473 UR - https://doi.org/10.1038/nature10144 DO - 10.1038/nature10144 ID - Carmeliet2011 ER - TY - JOUR AU - Ferrara, N. AU - Hillan, K. J. AU - Gerber, H. P. AU - Novotny, W. PY - 2004 DA - 2004// TI - Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer JO - Nat Rev Drug Discov VL - 3 UR - https://doi.org/10.1038/nrd1381 DO - 10.1038/nrd1381 ID - Ferrara2004 ER - TY - JOUR AU - Alevizakos, M. AU - Kaltsas, S. AU - Syrigos, K. N. PY - 2013 DA - 2013// TI - The VEGF pathway in lung cancer JO - Cancer Chemother Pharmacol VL - 72 UR - https://doi.org/10.1007/s00280-013-2298-3 DO - 10.1007/s00280-013-2298-3 ID - Alevizakos2013 ER - TY - JOUR AU - Sandler, A. AU - Gray, R. AU - Perry, M. C. PY - 2006 DA - 2006// TI - Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer JO - N Engl J Med. VL - 355 UR - https://doi.org/10.1056/NEJMoa061884 DO - 10.1056/NEJMoa061884 ID - Sandler2006 ER - TY - JOUR AU - Cohen, M. H. AU - Gootenberg, J. AU - Keegan, P. AU - Pazdur, R. PY - 2007 DA - 2007// TI - FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer JO - Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-6-713 DO - 10.1634/theoncologist.12-6-713 ID - Cohen2007 ER - TY - JOUR AU - O'Reilly, M. S. AU - Boehm, T. AU - Shing, Y. PY - 1997 DA - 1997// TI - Endostatin: an endogenous inhibitor of angiogenesis and tumor growth JO - Cell VL - 88 UR - https://doi.org/10.1016/S0092-8674(00)81848-6 DO - 10.1016/S0092-8674(00)81848-6 ID - O'Reilly1997 ER - TY - JOUR AU - Karamouzis, M. V. AU - Moschos, S. J. PY - 2009 DA - 2009// TI - The use of endostatin in the treatment of solid tumors JO - Expert Opin Biol Ther VL - 9 UR - https://doi.org/10.1517/14712590902882118 DO - 10.1517/14712590902882118 ID - Karamouzis2009 ER - TY - JOUR AU - Kim, Y. M. AU - Hwang, S. AU - Kim, Y. M. PY - 2002 DA - 2002// TI - Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1 JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M202771200 DO - 10.1074/jbc.M202771200 ID - Kim2002 ER - TY - JOUR AU - Song, H. F. AU - Liu, X. W. AU - Zhang, H. N. AU - Zhu, B. Z. AU - Yuan, S. J. AU - Liu, S. Y. PY - 2005 DA - 2005// TI - Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys JO - Acta Pharmacol Sin VL - 26 UR - https://doi.org/10.1111/j.1745-7254.2005.00009.x DO - 10.1111/j.1745-7254.2005.00009.x ID - Song2005 ER - TY - JOUR AU - Wang, J. AU - Sun, Y. AU - Liu, Y. AU - Yu, Q. PY - 2005 DA - 2005// TI - Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients JO - Zhongguo Fei Ai Za Zhi VL - 8 ID - Wang2005 ER - TY - JOUR AU - An, J. AU - Lv, W. PY - 2018 DA - 2018// TI - Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: a meta-analysis JO - Thorac Cancer VL - 9 UR - https://doi.org/10.1111/1759-7714.12626 DO - 10.1111/1759-7714.12626 ID - An2018 ER - TY - JOUR AU - Tierney, J. F. AU - Stewart, L. A. AU - Ghersi, D. AU - Burdett, S. AU - Sydes, M. R. PY - 2007 DA - 2007// TI - Practical methods for incorporating summary time-to-event data into meta-analysis JO - Trials. VL - 8 UR - https://doi.org/10.1186/1745-6215-8-16 DO - 10.1186/1745-6215-8-16 ID - Tierney2007 ER - TY - JOUR AU - Higgins, J. P. AU - Altman, D. G. AU - Gøtzsche, P. C. PY - 2011 DA - 2011// TI - The Cochrane Collaboration's tool for assessing risk of bias in randomised trials JO - BMJ VL - 343 UR - https://doi.org/10.1136/bmj.d5928 DO - 10.1136/bmj.d5928 ID - Higgins2011 ER - TY - STD TI - Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 5 May 2016. UR - http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp ID - ref18 ER - TY - JOUR AU - Gelman, A. AU - Rubin, D. PY - 1992 DA - 1992// TI - Inference from iterative simulation using multiple sequences JO - Statist Sci VL - 7 UR - https://doi.org/10.1214/ss/1177011136 DO - 10.1214/ss/1177011136 ID - Gelman1992 ER - TY - JOUR AU - Zarogoulidis, P. AU - Kontakiotis, T. AU - Karaiskos, T. PY - 2013 DA - 2013// TI - Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer[J] JO - Oncotargets Therapy VL - 2013 UR - https://doi.org/10.2147/OTT.S42245 DO - 10.2147/OTT.S42245 ID - Zarogoulidis2013 ER - TY - JOUR AU - Fukuda, M. AU - Kitazaki, T. AU - Ogawara, D. PY - 2019 DA - 2019// TI - Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: results of the Lung oncology group in Kyushu (LOGIK1201) JO - Lung Cancer VL - 132 UR - https://doi.org/10.1016/j.lungcan.2019.01.008 DO - 10.1016/j.lungcan.2019.01.008 ID - Fukuda2019 ER - TY - JOUR AU - Galetta, D. AU - Cinieri, S. AU - Pisconti, S. PY - 2015 DA - 2015// TI - Cisplatin/Pemetrexed followed by maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial JO - Clin Lung Cancer VL - 16 UR - https://doi.org/10.1016/j.cllc.2014.12.002 DO - 10.1016/j.cllc.2014.12.002 ID - Galetta2015 ER - TY - JOUR AU - Grønberg, B. H. AU - Bremnes, R. M. AU - Fløtten, O. PY - 2009 DA - 2009// TI - Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.9114 DO - 10.1200/JCO.2008.20.9114 ID - Grønberg2009 ER - TY - JOUR AU - Han, B. AU - Xiu, Q. AU - Wang, H. PY - 2011 DA - 2011// TI - A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer JO - J Thorac Oncol VL - 6 UR - https://doi.org/10.1097/JTO.0b013e3182166b6b DO - 10.1097/JTO.0b013e3182166b6b ID - Han2011 ER - TY - JOUR AU - Johnson, D. H. AU - Fehrenbacher, L. AU - Novotny, W. F. PY - 2004 DA - 2004// TI - Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.11.022 DO - 10.1200/JCO.2004.11.022 ID - Johnson2004 ER - TY - JOUR AU - Niho, S. AU - Kunitoh, H. AU - Nokihara, H. PY - 2012 DA - 2012// TI - Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer JO - Lung Cancer VL - 76 UR - https://doi.org/10.1016/j.lungcan.2011.12.005 DO - 10.1016/j.lungcan.2011.12.005 ID - Niho2012 ER - TY - JOUR AU - Patel, J. D. AU - Socinski, M. A. AU - Garon, E. B. PY - 2013 DA - 2013// TI - PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.47.9626 DO - 10.1200/JCO.2012.47.9626 ID - Patel2013 ER - TY - JOUR AU - Rodrigues-Pereira, J. AU - Kim, J. H. AU - Magallanes, M. PY - 2011 DA - 2011// TI - A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer JO - J Thorac Oncol VL - 6 UR - https://doi.org/10.1097/JTO.0b013e318226b5fa DO - 10.1097/JTO.0b013e318226b5fa ID - Rodrigues-Pereira2011 ER - TY - JOUR AU - Reck, M. AU - Pawel, J. AU - Zatloukal, P. PY - 2009 DA - 2009// TI - Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil JO - J Clin Oncol. VL - 27 UR - https://doi.org/10.1200/JCO.2007.14.5466 DO - 10.1200/JCO.2007.14.5466 ID - Reck2009 ER - TY - JOUR AU - Scagliotti, G. V. AU - Parikh, P. AU - Pawel, J. PY - 2008 DA - 2008// TI - Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.0375 DO - 10.1200/JCO.2007.15.0375 ID - Scagliotti2008 ER - TY - JOUR AU - Scagliotti, G. V. AU - Marinis, F. AU - Rinaldi, M. PY - 2002 DA - 2002// TI - Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.02.068 DO - 10.1200/JCO.2002.02.068 ID - Scagliotti2002 ER - TY - JOUR AU - Schiller, J. H. AU - Harrington, D. AU - Belani, C. P. PY - 2002 DA - 2002// TI - Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer JO - N Engl J Med VL - 346 UR - https://doi.org/10.1056/NEJMoa011954 DO - 10.1056/NEJMoa011954 ID - Schiller2002 ER - TY - JOUR AU - Smit, E. F. AU - Meerbeeck, J. P. AU - Lianes, P. PY - 2003 DA - 2003// TI - Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975 JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.03.195 DO - 10.1200/JCO.2003.03.195 ID - Smit2003 ER - TY - JOUR AU - Soria, J. C. AU - Márk, Z. AU - Zatloukal, P. PY - 2011 DA - 2011// TI - Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.37.2623 DO - 10.1200/JCO.2011.37.2623 ID - Soria2011 ER - TY - JOUR AU - Spigel, D. R. AU - Anthony Greco, F. AU - Waterhouse, D. M. PY - 2012 DA - 2012// TI - Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer JO - Lung Cancer VL - 78 UR - https://doi.org/10.1016/j.lungcan.2012.06.008 DO - 10.1016/j.lungcan.2012.06.008 ID - Spigel2012 ER - TY - JOUR AU - Spigel, D. R. AU - Hainsworth, J. D. AU - Joseph, M. J. PY - 2018 DA - 2018// TI - Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2 JO - Cancer VL - 124 UR - https://doi.org/10.1002/cncr.30986 DO - 10.1002/cncr.30986 ID - Spigel2018 ER - TY - JOUR AU - Treat, J. A. AU - Gonin, R. AU - Socinski, M. A. PY - 2010 DA - 2010// TI - A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdp352 DO - 10.1093/annonc/mdp352 ID - Treat2010 ER - TY - JOUR AU - Wu, Y. L. AU - Lu, S. AU - Cheng, Y. PY - 2014 DA - 2014// TI - Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer JO - Lung Cancer VL - 85 UR - https://doi.org/10.1016/j.lungcan.2014.07.007 DO - 10.1016/j.lungcan.2014.07.007 ID - Wu2014 ER - TY - JOUR AU - Zinner, R. G. AU - Obasaju, C. K. AU - Spigel, D. R. PY - 2015 DA - 2015// TI - PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000366 DO - 10.1097/JTO.0000000000000366 ID - Zinner2015 ER - TY - JOUR AU - Zhao, X. AU - Mei, K. AU - Cai, X. PY - 2012 DA - 2012// TI - A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9631-7 DO - 10.1007/s10637-011-9631-7 ID - Zhao2012 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. L. AU - Chen, G. PY - 2015 DA - 2015// TI - BEYOND: a randomized, double-blind, placebo-controlled, Multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.4424 DO - 10.1200/JCO.2014.59.4424 ID - Zhou2015 ER - TY - JOUR AU - Marinis, D. E. AU - F, Bidoli P, Luciani A, PY - 2017 DA - 2017// TI - EAGLES study: first-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer JO - Anticancer Res VL - 37 UR - https://doi.org/10.21873/anticanres.11586 DO - 10.21873/anticanres.11586 ID - Marinis2017 ER - TY - JOUR AU - Yu, X. AU - Zhang, L. AU - Chen, J. PY - 2018 DA - 2018// TI - Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study JO - Open Med VL - 13 UR - https://doi.org/10.1515/med-2018-0022 DO - 10.1515/med-2018-0022 ID - Yu2018 ER - TY - JOUR AU - Schuette, W. AU - Schneider, C. P. AU - Engel-Riedel, W. PY - 2017 DA - 2017// TI - 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer JO - Lung Cancer VL - 8 ID - Schuette2017 ER - TY - JOUR AU - Zhou, S. AU - Zuo, L. AU - He, X. AU - Pi, J. AU - Jin, J. AU - Shi, Y. PY - 2018 DA - 2018// TI - Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: a retrospective comparison with standard chemotherapy JO - Thorac Cancer VL - 9 UR - https://doi.org/10.1111/1759-7714.12827 DO - 10.1111/1759-7714.12827 ID - Zhou2018 ER - TY - JOUR AU - Liu, Z. J. AU - Wang, J. AU - Wei, X. Y. PY - 2012 DA - 2012// TI - Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer JO - J Cancer Res Clin Oncol VL - 138 UR - https://doi.org/10.1007/s00432-012-1167-5 DO - 10.1007/s00432-012-1167-5 ID - Liu2012 ER - TY - JOUR AU - Sun, Y. AU - Wang, J. W. AU - Liu, Y. Y. PY - 2013 DA - 2013// TI - Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer JO - Thorac Cancer VL - 4 UR - https://doi.org/10.1111/1759-7714.12050 DO - 10.1111/1759-7714.12050 ID - Sun2013 ER -